JAIC
HUMA icon

Josh Arnold Investment Consultant’s Humacyte HUMA Stock Holding History

Josh Arnold Investment Consultant’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-38,000
Closed -$109K – 30
2023
Q2 		$109K Buy
+38,000
New +$137K 0.11% 26
2022
Q3 		– Sell
-22,000
Closed -$71K – 14
2022
Q2 		$71K Sell
22,000
-14,171
-39% -$78.8K 0.09% 19
2022
Q1 		$255K Buy
+36,171
New +$211K 0.24% 18

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Josh Arnold Investment Consultant's HUMA Position: Q3 2023 in Review

Josh Arnold Investment Consultant sold out of Humacyte (HUMA) in Q3 2023, closing a stake of 38,000 shares — an estimated $109K sold.

Josh Arnold Investment Consultant first reported a position in HUMA in Q1 2022 and held it in 3 quarters. The position peaked at $255K in Q1 2022. 83 funds tracked by Wall St. Rank hold HUMA as of Q3 2023.

  • Josh Arnold Investment Consultant reported no remaining Humacyte position as of Q3 2023 after selling out during the quarter.
  • Josh Arnold Investment Consultant sold 38,000 Humacyte shares in Q3 2023, an estimated $109K.
  • Josh Arnold Investment Consultant first reported a position in Humacyte in Q1 2022 and held it in 3 quarters.
  • Josh Arnold Investment Consultant's Humacyte position peaked at $255K in Q1 2022.
  • 83 funds tracked by Wall St. Rank held Humacyte as of Q3 2023.

Based on Josh Arnold Investment Consultant's 13F filing for Q3 2023, filed 14 Nov 2023.